A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Male and female, ages 18 to 70 years
• Body weight \>40 kg, body mass index (BMI) of 18 to 40 kg/m2
• Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit
• Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.
Locations
Other Locations
China
Shanghai Skin Disease Hospital
RECRUITING
Shanghai
Contact Information
Primary
Yang Zhang
yang_zhang@usynova.com
+8613636393195
Time Frame
Start Date: 2025-10-21
Estimated Completion Date: 2026-05-30
Participants
Target number of participants: 140
Treatments
Experimental: dose level 1
Experimental: dose level 2
Experimental: dose level 3
Placebo_comparator: placebo
Related Therapeutic Areas
Sponsors
Leads: Usynova Pharmaceuticals Ltd.